Other ancillary courses: Masters in Molecular Oncology, Spain (Online)

Experience: 3+ Years

Areas of Specialization:

Geriatric Oncology, Targeted therapy, CAR- T cell therapy, Stem cell transplant

Overseas experience:

• Observer at Department of Thoracic Oncology at Stanford Hospital, Palo Alto. 2019.
• Observer at Department of Gynae Oncology at Guys and St. Thomas, London. 2020.

Publications:

• Lal Darbari, Tewani Rohan, Sharma Hemant and Jain Sunjay. Acalculous Cholecystitis in Primary Dengue Fever Patients. IJFANS. Vol.3, Iss.1, Jan-Mar 2014
• Darbari Lal, Rohan Tewani, Mala Chhabra, Akshay Chandra Dhariwal. Scrub Typhus Meningitis from Urban Delhi – An Atypical Presentation. J. Commun. Dis. 2015; 47(1): 19- 20
• Lal Darbari, Sharma Hemant, Tewani Rohan, Mahi Ishani. Correlation of Serum Lipids with HbA1c in Individuals with Type 2 Diabetes Mellitus. Int J Med Res Prof.2019 Jan; 5(1); 334-37.
• Lal Darbari, Sharma Hemant, Tewani Rohan, Mahi Ishani. Serum Cystatin C as a Marker for Early Renal Impairment in Individuals with Type 2 Diabetes Mellitus. Int J Med Res Prof.2019 Sept; 5(5); 63-66.
• Tewani R. Being a resident in the COVID era: It changed everything. Indian J Med Paediatr Oncol 2020;41:161-2.
• Abraham G, Noronha V, Rajappa S, Agarwal A, Batra U, Somani N, Raja T, Patil S, Kaushal AM, Joshi A, Radhakrishnan V, Singh N, Babu G, Tewani R, Baghmar S, Dodagoudar C, Ananthakrishnan R, Haragadde Poppareddy S, Sharma V, Menon N, M Patil V, Joshi A, Gupta S, Prabhash K, Bajpai J. The clinical utility and safety of short-course immune checkpoint inhibitors in multiple tumours-A real-world multicentric study from India. Int J Cancer. 2021 Nov 9. doi: 10.1002/ijc.33868.
• Syed Nusrath, Subramanyeshwar R. Thammineedi,Kalidindi Venkata Vijaya Narsimha Raju,Sujith C. Patnaik,Ajesh R. Saksena,Jaya Karthik, Madhunarayana Basude, Pavan Kumar J, Srijan Shukla,Vishal B. Rao ,Kishore Kumar C,Swathi Gujjuru, Rohan Tewani, Tasneem Rushdie, Rashmi Sudhir, Lynette M. Smith, Chandrakanth Are. Factors associated with pathologic complete response following neoadjuvant chemoradiation and esophagectomy for carcinoma of esophagus and gastroesophageal junction. J Surg Oncol. 2022;1–8. DOI: 10.1002/jso.27103.